OMRF has discovered a targeted therapy that could improve treatment and long-term outcomes for ovarian cancer.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
Cancer often returns after successful therapy, but why?
The Saxon program provides military academy students with an opportunity to work alongside OMRF senior scientists.
Research team’s new findings recently published in Nature Communications.